Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage

Overview

To delineate the effect of MSM on osteoarthritis

Full Title of Study: “The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: September 2013

Detailed Description

Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).

Interventions

  • Drug: MethylSulfonylMethane (MSM)
    • Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
  • Drug: Placebo

Arms, Groups and Cohorts

  • Experimental: MSM group
    • Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
  • Placebo Comparator: Placebo Group
    • Placebo 3 gr twice a day for 26 weeks (6 gr/day total)

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants with improved Mobility
    • Time Frame: 26 weeks
    • Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)

Secondary Measures

  • Pain Scores on the Visual Analog Scale
    • Time Frame: 26 weeks
    • On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life)

Participating in This Clinical Trial

Inclusion Criteria

  • Knee and hip OA – men and women >45 years of age Exclusion Criteria:

  • any other type of arthritis – chronic pain syndrome – arthroscopic surgery in the past 8 months – intra-articular corticosteroidsin the past 8 months – hyaluronic acid injections in the past 8 months – narcotic pain killers use – renal or hepatic disease – body mass index (BMI) >45 kg/m2 – cancer

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • G.Papanikolaou Research Group
  • Provider of Information About this Clinical Study
    • Principal Investigator: Thomas Pagonis, Orthopaedic Surgeon – G.Papanikolaou Research Group
  • Overall Official(s)
    • Thomas Pagonis, MD, PhD, Principal Investigator, Aristotle’s University of Thessaloniki
  • Overall Contact(s)
    • Thomas Pagonis, MD, PhD, 00306980488686, iatros1@yahoo.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.